Rakesh P. Prajapati, Manisha V. Kalariya, Sachin K. Parmar
Rakesh P. Prajapati1, Manisha V. Kalariya2, Dr. Sachin K. Parmar3*
1Department of Pharmacognosy, Bhagwan Mahavir College of Pharmacy, Gujarat Technological University, Surat - 395017, Gujarat, India.
2Department of Pharmacognosy, B. K. Mody Govt. Pharmacy College, Gujarat Technological University, Rajkot - 360003, Gujarat, India.
3Department of Pharmaceutical Sciences, Saurashtra University, Rajkot - 360003, Gujarat, India.
Volume - 14,
Issue - 10,
Year - 2021
Context: Psychosis is a mental disorder, which is characterized as the reducing association with certainty and conviction. Around 1-2% of the world's population suffers from psychosis. The people affected by psychosis have hallucinations, delusions, forgetfulness, abolition, and anhedonia. Currently existing most of the anti- psychotic medications express the adverse drug reactions. Thus for the management of psychosis, satisfactory and adequate remedies are not available. Lagenaria siceraria (Molina) Standley (LS) (Cucurbitaceae) fruits, popularly known as “bottle gourd” (English) and “Lauki” (Hindi), exhibit numerous intrinsic therapeutic properties and actions. However limited scientific investigations have been performed to determine the neuroprotective potential of LS fruits. With this background, the present study was intended to investigate LS fruits for the assessment of anti-psychotic activity. Aims and Objectives: The rationale of this study was to evaluate the anti-psychotic activity of the phytocompound rich fractions of the methanolic extract of LS i.e., chloroform fraction of the methanolic extract (CFME), and acetone fraction of the methanolic extract (AFME) by using experimental models of cataleptic and stereotypic behavior in Swiss Albino mice. Materials and Methods: Haloperidol-induced catalepsy and apomorphine-induced stereotypy were the experimental screening tests performed for the assessment of anti-psychotic activity of the phytocompound rich fractions of methanolic extract of LS fruits at the doses of 100, 200, and 400mg/kg, p.o. in mice. Results: CFME and AFME, 100-400 mg/kg, significantly reduced cataleptic score and stereotypic behavior in mice, in dose-dependent manner. At doses of 200 and 400mg/ kg, AFME (P<0.001) exhibited more significant effect than CFME. In addition CFME and AFME did not generate motor dysfunction in mice. Preliminary phytochemical screening on CFME revealed the presence of saponins, phytosterols, and terpenoids, while phytochemical investigations on AFME indicated the presence of saponins, phenolic compounds, flavonoids and tannins. This was the first scientific report, which indicates that the LS fruits exhibit anti-psychotic action, confirming the folklore claims. Future investigations and studies should emphasize separation, characterization, and identification of the bioactive phytoconstituents and also on evaluating the precise mechanism involved in the anti-psychotic activity of both the fractions.
Cite this article:
Rakesh P. Prajapati, Manisha V. Kalariya, Sachin K. Parmar. Evaluation of Anti-Psychotic potential of Phytocompound rich Fractions of Methanolic extract of Lagenaria siceraria (Bottle Gourd) fruits in Murine Models of Schizophrenia. Research Journal of Pharmacy and Technology. 2021; 14(10):5242-8. doi: 10.52711/0974-360X.2021.00913
Rakesh P. Prajapati, Manisha V. Kalariya, Sachin K. Parmar. Evaluation of Anti-Psychotic potential of Phytocompound rich Fractions of Methanolic extract of Lagenaria siceraria (Bottle Gourd) fruits in Murine Models of Schizophrenia. Research Journal of Pharmacy and Technology. 2021; 14(10):5242-8. doi: 10.52711/0974-360X.2021.00913 Available on: https://rjptonline.org/AbstractView.aspx?PID=2021-14-10-31
1. Yuliya S, Prokopenko YS, Lina O, Perekhoda LO, Victoriya A. Docking studies of biologically active substances from plant extracts with anti-convulsant activity. J. Appl. Pharmaceutical Sci. 2019; 9(1): 66-72.
2. Balasubramaninan A, Ramalingam K, Rahul Radhakrishnan R, John R, Arafath N. Comparative efficacy of Typical and Atypical anti-psychotics in the treatment of Acute Mania. Research J Pharm. and Tech. 2019; 12(6): 2804-2808.
3. Veerni V, Ratna J, Vempadapu M, Raj KK, Mugada V. Risk of Cardiovascular Disease in Schizophrenia: A Mini Review. Asian J. Res. Pharm. Sci. 2019; 9(2): 131-136.
4. Mathew VK, Sam KG, Samuel B, Das AK. Epidemiology of Schizophrenia in an Indian Hospital. Research J. Pharm. and Tech. 2020; 13(1): 219-223.
5. Freud S. The loss of reality in neurosis and psychosis. In: The Standard Edition of the Complete Psychological Works of Sigmund Freud (1923-1925). Vol. 19, Vintage Publishing, London, United Kingdom, 1961; pp. 181-188.
6. Morrison AP. 2001. The interpretation of intrusions in psychosis: An integrative cognitive approach to hallucinations and delusions. Behav. Cogn. Psychother. 2001; 29: 257-276.
7. Freeman D, Garety PA. Connecting neurosis and psychosis: The direct influence of emotion on delusions and hallucinations. Behav. Cogn. Psychother. 2003; 41: 923-947.
8. Maudsley H. Hallucinations of the senses. Fortnightly Review. 1878; 24: 370-386.
9. Lincoln TM. Are delusions understandable? From the mechanisms of delusion formation and maintenance to the development of novel interventions. Zeitschrift fur Psychologie (Journal of Psychology). 2018; 226: 139-141.
10. Boydell KM, Stasiulis E, Volpe T, Gladstone B. A descriptive review of qualitative studies in first episode psychosis. Early Interv Psychia. 2010; 4: 7-24
11. Parle M, Sharma K. Schizophrenia: A review. Int. Res. J. Pharm. 2013; 4: 52-55.
12. Sanberg PR, Bunsey MD, Giordano M, Norman AB. The catalepsy test: its ups and down. Behav. Neurol. 1988; 102(5): 748-759.
13. Rasmussen K, Hsu MA, Noone S, Johnson BG, Thompson LK, Hemrick-Luecke SK. The orexin-1 antagonist SB-334867 blocks anti-psychotic treatment emergent catalepsy: implications for the treatment of extra pyramidal symptoms. Schizophrenia Bulletin. 2007; 33(6): 1291-1297.
14. Jankovic J. Differential diagnosis and etiology of tics. Adv. Neurol. 2001; 85: 15-29.
15. Pedro BM, Pilowsky LS, Costa DC. Stereotypy, schizophrenia, and dopamine D2 receptor binding in the basal ganglia. Psychol. Med. 1994; 24(2): 423-429.
16. Mateen FJ, Josephs KA. The clinical spectrum of stereotypies in frontotemporal lobar degeneration. Mov. Disord. 2009; 24(8): 1237-1240.
17. Mendez MF, Shapira JS. The spectrum of recurrent thoughts and behaviors in frontotemporal dementia. CNS Spect. 2008; 13(3): 202-208.
18. Barnes TR. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J. Psychopharmacol. 2011; 25(5): 567-620.
19. Schmidt D, Loscher W. Drug resistance in epilepsy: putative neurobiological and clinical mechanisms. Epilepsia. 2005; 46: 858-877.
20. Loscher W. Current status and future directions in the pharmacotherapy of epilepsy. Trends Pharmacol. Sci. 2002; 23: 113-118.
21. McNamara JO. Emerging insights into the genesis of epilepsy. Nature. 1999; 399(6738 Suppl.): A15-22.
22. Brodie MJ, Kwan P. The star systems: overview and use in determining antiepileptic drug choice. CNS Drugs. 2001; 15: 1-12.
23. Veerapur VP, Desai PP, Vijayakumar S. Pharmacognostic and Preliminary Phytochemical Screening of Sesbania grandiflora root. Res. J. Pharmacognosy and Phytochem. 2018; 10(4): 285-290.
24. Settu S, Arunachalam S. Comparison of Phytochemical analysis and In vitro Pharmacological activities of most commonly available medicinal plants belonging to the Cucurbitaceae family. Research J. Pharm. and Tech. 2019; 12(4): 1541-1546.
25. Kirtikar KR. Indian medicinal Plants, Oriental Enterprises, Dehradun, India, 2012; pp.722- 723.
26. Deshmukh DB, Sherkar MR. Evaluation of In Vivo Analgesic and Anti-Inflammatory Activity of Ethanolic Extract of Medicinal Plant- Lagenaria siceraria. Asian J. Pharm. Tech. 2019; 9(2): 75- 78.
27. Dahikar SB. In Vitro Antimicrobial Activity of Fruit Extracts of Lagenaria Siceraria (Mol.). Res. J. Pharmacognosy and Phytochem. 2018; 10(2): 183-186.
28. Tarange RG, Kharat JS, Jedage HD, Manjunath KP. Phytochemical screening for Antioxidant and Antifungal activity of Lagenaria siceraria (Molina) Standl. leaf extract. Res. J. Pharmacognosy and Phytochem. 2019; 11(3): 155-159.
29. Prajapati R, Umbarkar R, Parmar S, Sheth NR. Antidepressant like activity of Lagenaria siceraia (Molina) Standley fruits by evaluation of the forced swim behavior in Rats. Int. J. Nutr. Pharmacol. Neurol. Dis. 2011; 1: 152-156.
30. Khandelwal KR. Preliminary phytochemical screening. In: Practical Pharmacognosy, 6th ed., Nirali Prakashan, Pune, 2006; pp. 149-153.
31. OECD (Organization for Economic Co-operation and Development). Guidance Document on Acute Oral Toxicity. Environmental Health and Safety Monograph Series on Testing and Assessment, 2000; pp. 24
32. Pemminati S, Nair V, Dorababu P, Gopalakrishna HN. Effect of ethanolic leaf extract of Ocimum sanctum on haloperidol-induced catalepsy in albino mice. Ind. J. Pharmacol. 2007; 39(2): 87-89.
33. Kenneth SK, Kenneth ID. Genetic control of apomorphine induced climbing behavior in two inbred mouse strains. Brain Res. 1984; 293: 343-351.
34. Porsolt RD, Moser PC, Moser V. Behavioral indices in anti- psychotic drug discovery. J. Pharmacol. Exp. Ther. 2010; 333: 632-638.
35. Shin HW, Chung SJ. Drug-induced Parkinsonism. J. Clin. Neurol. 2012; 8: 15-21.
36. Protais J, Schwartz JC. Climbing behavior induced by apomorphine in mice: a simple test for the study of dopamine receptors in striatum. Psychopharmacol. (Berl.) 1976; 50(1): 1-6.
37. Jones C, Watson D, Fone K. Animal models of schizophrenia, Br. J. Pharmacol. 2011: 1162-1194.
38. Lau HC, Wang JL, Hsu M, Liu E. Does the dopamine hypothesis explain schizophrenia? Rev. Neuroscience. 2013; 24: 389-400.
39. David P, Robert L, Konicki E, Owen W, Alan B. 1990. Neurochemical and Neural Mechanisms of Positive and Negative Symptoms in Schizophrenia. Schizophrenia: Positive and Negative Symptoms and Syndromes. Mod. Trend. Psychiatry. 1990; 24:124- 151.
40. Liemburg EJ, Knegtering H, Klein HC, Kortekaas R, Aleman A. Anti-psychotic medication and prefrontal cortex activation: a review of neuroimaging findings. Euro. J. Neuropsychopharmacol. 2012; 22(6): 387-400.
41. McDonald C, Murphy KC. The new genetics of schizophrenia. The Psychiatric Clinics of North America. 2003; 26(1): 41-63.
42. Atodariya PP, Raj AA, Jain VC. Simultaneous Estimation of Lamotrigine and Clozapine by Simultaneous equation method in their Synthetic Mixture which use in Schizophrenia. Asian J. Pharm. Ana. 2015; 5(2): 79-85.
43. Kahale VP, Upadhay PR, Mhaiskar AJ, Shelat PS, Mundhada DR. To Access the Efficacy of Rutin on 6-Hydroxydopamine induced Animal Model of Memory Impairment in Parkinson’s disease. Research J. Pharmacology and Pharmacodynamics. 2013; 5(6): 331-336.
44. Baul HS, Rajiniraja M. Molecular Docking Studies of Selected Flavonoids on inducible Nitric Oxide Synthase (iNOS) in Parkinson’s Disease. Research J. Pharm. and Tech., 2018; 11(8): 3685-3688.